Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 12;11(9):1358.
doi: 10.3390/cancers11091358.

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

Ugo Testa  1 , Elvira Pelosi  2 , Germana Castelli  3
Affiliations
Review

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

Ugo Testa et al. Cancers (Basel). .

Abstract

The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoid dendritic neoplasm (BPDCN). Importantly, CD123 is expressed at both the level of leukemic stem cells (LSCs) and more differentiated leukemic blasts, which makes CD123 an attractive therapeutic target. Various agents have been developed as drugs able to target CD123 on malignant leukemic cells and on the normal counterpart. Tagraxofusp (SL401, Stemline Therapeutics), a recombinant protein composed of a truncated diphtheria toxin payload fused to IL-3, was approved for use in patients with BPDCN in December of 2018 and showed some clinical activity in AML. Different monoclonal antibodies directed against CD123 are under evaluation as antileukemic drugs, showing promising results either for the treatment of AML minimal residual disease or of relapsing/refractory AML or BPDCN. Finally, recent studies are exploring T cell expressing CD123 chimeric antigen receptor-modified T-cells (CAR T) as a new immunotherapy for the treatment of refractory/relapsing AML and BPDCN. In December of 2018, MB-102 CD123 CAR T developed by Mustang Bio Inc. received the Orphan Drug Designation for the treatment of BPDCN. In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies.

Keywords: acute myeloid leukemia; biomarker; interleukin-3; interleukin-3 receptor; leukemia; leukemic stem cells; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Dohner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N. Engl. J. Med. 2015;373:1136–1152. doi: 10.1056/NEJMra1406184. - DOI - PubMed
    1. Hartman L., Metzler K.H. Clonal hematopoiesis and preleukemia–Genetics, biology, and clinical implications. Genes Chromosom. Cancer. 2019 doi: 10.1002/gcc.22756. - DOI - PubMed
    1. Valent P., Kern W., Hoermann G., Feenstra J.M., Sotlar K., Pfeilstocker M. Clonal hematopoiesis with oncogenic potential (CHOP): Separation from CHIP and roads to AML. Int. J. Mol. Sci. 2019;20:789. doi: 10.3390/ijms20030789. - DOI - PMC - PubMed
    1. Lindsley R.C., Mar B.G., Mazzola E., Grauman P.V., Shareef S., Allen S.L., Pigneux A., Wetzler M., Stuart R.K., Erba H.P., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1267–1276. doi: 10.1182/blood-2014-11-610543. - DOI - PMC - PubMed
    1. Dohner H., Estey E., Grimwade D., Amadori S., Appelbaum F.R., Buchner T., Dombret H., Ebert B.L., Fenaux P., Larson R.A., et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447. doi: 10.1182/blood-2016-08-733196. - DOI - PMC - PubMed

LinkOut - more resources